Categories Earnings, Health Care
Earnings Summary: Gilead Sciences reports higher Q2 revenue and profit
Gilead Sciences, Inc. (NASDAQ: GILD), a leading research-based biopharmaceutical company, has reported an increase in revenues and adjusted earnings for the second quarter of 2024.
- Second-quarter revenue increased 5% from last year to $7.0 billion, aided by higher product sales in HIV, Liver Disease, and Oncology
- Earnings, on a per-share basis, were $1.29 in the second quarter, compared to $0.83 in the same period in 2023
- Adjusted earnings per share increased to $2.01 in the June quarter from $1.34 in the prior-year period
- Net income attributable to Gilead advanced to $1.61 billion in Q2 from $1.05 billion in the year-ago quarter
- As of June 30, 2024, the company had $2.8 billion of cash, cash equivalents, and marketable debt securities, vs. $8.4 billion a year earlier
- During the quarter, Gilead generated $1.3 billion in operating cash flow; it paid dividends of $972 million and repurchased $100 million of common stock
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key metrics from Biogen’s (BIIB) Q4 2024 earnings results
Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today. Total revenue increased 3% year-over-year to $2.5 billion. Net income attributable to Biogen Inc. was $266.8 million,
Important takeaways from Coca-Cola’s (KO) Q4 2024 earnings
The Coca-Cola Company (NYSE: KO) has wrapped up fiscal 2024 on an upbeat note, reporting stronger-than-expected results for the final quarter of the year. Encouraged by the growth in sales
Walt Disney (DIS): A look at the performance of the streaming business in 1Q25
Shares of The Walt Disney Company (NYSE: DIS) dropped 1% on Tuesday. The stock has gained 6% over the past three months. The company delivered top and bottom line growth
